Rating of in vitro cytotoxicity activities and anti-xanthine oxidase activities of some non-proteoneogenic amino acid derivatives by molecular docking and molecular dynamics studies

Basit Öğe Kaydı
dc.contributor.authorZuhal Alım
dc.contributor.authorSerap Yalçın Azarkan
dc.contributor.authorNamık Kılınç
dc.contributor.authorEbru Akkemik
dc.date.accessioned2025-05-13T07:00:24Z
dc.date.available2025-05-13T07:00:24Z
dc.date.issued2025-09
dc.departmentFakülteler, Mühendislik Fakültesi, Gıda Mühendisliği Bölümü
dc.description.abstractHyperuricemia is a chronic disease closely associated with many pathological conditions, including cancer, which occur due to increased uric acid levels. Xanthine Oxidase (XO) facilitates the stepwise conversion of hypoxanthine to xanthine and subsequently to uric acid, serving a crucial function in purine metabolism. XO inhibitors are the most important therapeutic agents for the control of hyperuricemia. The fact that existing XO inhibitors have serious side effects has made it necessary to describe original, impressive inhibitors with minor side effects. In this study, since the close relationship between hyperuricemia and cancer, the inhibition effects of some non-proteogenic amino acid derivatives (1-4) on XO activity and their cytotoxic effects on triple-negative breast cancer cell line (MDA-MB-231) were examined together. The inhibition effects of molecules 1-4 on XO activity were determined by IC50 values, and for XO, IC50 values of 1-4 were found to be 1.338 µM, 1.357 µM, 1.788 µM, 1.228 µM respectively. The cytotoxic effect of the molecules (1-4) on MDA-MB-231 cell lines was investigated by XTT analysis. According to the results obtained, it is seen that the effect of the 2nd (IC50:98.55 µM) molecule is more toxic on the cells than the others and molecule 2 demonstrated significant inhibition of cell migration in MDA-MB-231 cells in a compared to the untreated control. The study was supported by molecular docking and molecular dynamics and ADME analyses. In conclusion, the results of this study may be useful in the design of XO inhibitor drugs for the treatment of hyperuricemia by contributing to the synthesis of new, effective amino acid-derived XO inhibitors with fewer side effects.
dc.identifier.citationAlım, Z., Azarkan, S. Y., Kılınç, N., & Akkemik, E. (2025). Rating of In Vitro Cytotoxicity Activities and Anti-Xanthine Oxidase Activities of Some Non-Proteoneogenic Amino Acid Derivatives by Molecular Docking and Molecular Dynamics Studies. Journal of Molecular Structure, 142497.
dc.identifier.doi10.1016/j.molstruc.2025.142497
dc.identifier.issn0022-2860
dc.identifier.scopus2-s2.0-105004025835
dc.identifier.urihttps://doi.org/10.1016/j.molstruc.2025.142497
dc.identifier.urihttps://hdl.handle.net/20.500.12604/8662
dc.identifier.volume1340
dc.indekslendigikaynakScopus
dc.institutionauthorAkkemik, Ebru
dc.institutionauthorid0000-0002-4177-4884
dc.publisherElsevier BV
dc.relation.ispartofJournal of Molecular Structure
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBreast cancer
dc.subjectCytotoxicity
dc.subjectInhibition
dc.subjectMolecular docking
dc.subjectXanthine oxidase
dc.titleRating of in vitro cytotoxicity activities and anti-xanthine oxidase activities of some non-proteoneogenic amino acid derivatives by molecular docking and molecular dynamics studies
dc.typejournal-article
oaire.citation.volume1340

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Ebru-Akkemik-2025.pdf
Boyut:
7.15 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
2) Makale